CVS Health
CVS SP500 Healthcare
KÖP
72/100
Rank 20 av 500
91.37 USD
+2.09% idag
Live
Kursutveckling (180 dagar)
CVS
OMX30 (normaliserad)
Kursutveckling vs OMX30
1 dag
+2.09%
+2.6% vs OMX30
1 vecka
-0.76%
-0.1% vs OMX30
1 månad
+11.30%
+8.9% vs OMX30
3 månader
+12.87%
+15.1% vs OMX30
6 månader
+19.30%
+2.6% vs OMX30
Fundamentala nyckeltal
40.1
10.9
0.25
1.5
0.3
11.9
+63.1%
+6.1%
0.7%
4.1%
3.8%
2.7%
101%
0.87
3.0%
116.6B
STRONG_BUY
Riktkurs: 103 USD
(26 analytiker)
AI-analys
29.4
0.0
72.0
MEDEL
Kort sikt (3 månader)
75/100Stark teknisk signal med score 29.4 och Bollinger Bands-breakout. Hälsovård-tema stöder.
Lång sikt (3 år)
65/100Hälsovård gynnas av åldrande befolkning och bioteknik-framsteg enligt makroklimatet.
Stark teknisk momentum i hälsovårdssektor som gynnas av demografiska trender och bioteknik-utveckling.
- Ingen specifik information om bolaget i artiklarna
Senaste nyheter
Lilly’s GLP-1 medications will soon be covered by CVS, potentially opening access for millions of Americans
That means millions more Americans may get access to Lilly’s new GLP-1 pill Foundayo or the GLP-1 injection Zepbound.
CVS to restore coverage of Zepbound, add Eli Lilly's obesity pill to drug plans
CVS will add Zepbound coverage on Oct. 1, and start covering Lilly's newly approved Foundayo pill on June 1.
CVS to restore coverage of Zepbound, add Eli Lilly's obesity pill to drug plans
CVS will add Zepbound coverage on Oct. 1, and start covering Lilly's newly approved Foundayo pill on June 1.
CVS to restore coverage of Zepbound, add Eli Lilly's obesity pill to drug plans
CVS will add Zepbound coverage on Oct. 1, and start covering Lilly's newly approved Foundayo pill on June 1.